NASDAQ Biotechnology Index

NASDAQ Biotechnology Index is a stock market index designed to track the performance of biotechnology companies listed on the NASDAQ stock exchange, which is owned by Nasdaq, Inc. and is home to companies like Gilead Sciences, Amgen, and Biogen. The index is often used as a benchmark for the biotechnology industry, which includes companies like Celgene, Regeneron Pharmaceuticals, and Illumina. The NASDAQ Biotechnology Index is calculated and maintained by Nasdaq, Inc., which also calculates and maintains other indexes like the NASDAQ Composite and the NASDAQ-100. The index is widely followed by investors, including those at Fidelity Investments, Vanguard Group, and BlackRock.

● Introduction

The NASDAQ Biotechnology Index is a modified market capitalization-weighted index, which means that the largest companies in the index, such as Johnson & Johnson, Pfizer, and Merck & Co., have a greater influence on the index's performance. The index is designed to track the performance of companies in the biotechnology industry, which includes companies involved in the research, development, and commercialization of biotechnology products, such as genetic engineering and gene therapy. Companies like UnitedHealth Group, CVS Health, and Express Scripts Holding are also impacted by the performance of the biotechnology industry. The index is often used by investors, including those at State Street Corporation, T. Rowe Price, and Capital Group Companies, as a benchmark for their investments in the biotechnology sector, which includes companies like Alexion Pharmaceuticals, Incyte, and Seattle Genetics.

● History

The NASDAQ Biotechnology Index was launched in 1993, during a period of rapid growth in the biotechnology industry, which was driven by companies like Genentech, Chiron Corporation, and Cetus Corporation. The index was created to provide investors with a benchmark for the performance of biotechnology companies, which were becoming increasingly important in the pharmaceutical industry, with companies like GlaxoSmithKline, AstraZeneca, and Eli Lilly and Company. Over the years, the index has undergone several changes, including the addition of new companies like Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sangamo Therapeutics, and the removal of others, such as Human Genome Sciences and Pharmasset. The index has also been affected by major events in the biotechnology industry, such as the Human Genome Project, which was led by Francis Collins and involved companies like Illumina, Life Technologies, and Affymetrix.

● Composition

The NASDAQ Biotechnology Index is composed of companies listed on the NASDAQ stock exchange, which is also home to companies like Microsoft, Amazon, and Facebook. The index includes companies like Gilead Sciences, Amgen, and Biogen, which are among the largest and most well-established companies in the biotechnology industry. The index also includes smaller companies like Exelixis, Puma Biotechnology, and Clovis Oncology, which are involved in the development of new biotechnology products, such as immunotherapy and gene editing. The companies in the index are selected based on their market capitalization, liquidity, and other criteria, such as their involvement in the biotechnology industry and their listing on the NASDAQ stock exchange, which is regulated by the Securities and Exchange Commission.

● Performance

The NASDAQ Biotechnology Index has experienced significant volatility over the years, with periods of rapid growth and decline, driven by companies like Celgene, Regeneron Pharmaceuticals, and Illumina. The index has been affected by a range of factors, including changes in the biotechnology industry, such as the development of new biotechnology products and the approval of new drugs by the Food and Drug Administration. The index has also been influenced by broader market trends, such as the performance of the S&P 500 and the Dow Jones Industrial Average, which are followed by investors at Goldman Sachs, Morgan Stanley, and JPMorgan Chase. In recent years, the index has been driven by the performance of companies like Moderna Therapeutics, CRISPR Therapeutics, and Editas Medicine, which are involved in the development of new biotechnology products, such as mRNA therapy and gene editing.

● Trading

The NASDAQ Biotechnology Index is traded on the NASDAQ stock exchange, which is also home to companies like Apple, Google, and Intel. The index is available for trading through a range of financial instruments, including exchange-traded funds like the iShares NASDAQ Biotechnology ETF and the SPDR S&P Biotech ETF, which are offered by companies like BlackRock, Vanguard Group, and State Street Corporation. The index is also available for trading through options and futures contracts, which are listed on exchanges like the Chicago Board Options Exchange and the Intercontinental Exchange. Investors, including those at Fidelity Investments, Charles Schwab Corporation, and E\*TRADE, can trade the index through a range of brokerage firms, such as Merrill Lynch and Wells Fargo Advisors.

● Investment Products

The NASDAQ Biotechnology Index is used as the basis for a range of investment products, including exchange-traded funds like the iShares NASDAQ Biotechnology ETF and the SPDR S&P Biotech ETF, which are offered by companies like BlackRock, Vanguard Group, and State Street Corporation. The index is also used as the basis for mutual funds, such as the T. Rowe Price Health Sciences Fund and the Fidelity Select Biotechnology Portfolio, which are offered by companies like T. Rowe Price and Fidelity Investments. Additionally, the index is used as the basis for options and futures contracts, which are listed on exchanges like the Chicago Board Options Exchange and the Intercontinental Exchange, and are traded by investors at Goldman Sachs, Morgan Stanley, and JPMorgan Chase. The index is also used by investors, including those at CalPERS, CalSTRS, and New York State Common Retirement Fund, as a benchmark for their investments in the biotechnology sector, which includes companies like Alexion Pharmaceuticals, Incyte, and Seattle Genetics.